ODM-201是一种强效的雄激素受体拮抗剂，Ki值为11nM，IC50值为26nM。
Cas No.:1297538-32-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ODM-201 is a potent antagonist of the androgen receptor (AR) with a Ki value of 11nM and an IC50 value of 26nM [1]. ODM-201 maintains the binding conformation in the F877L-mutated pocket through hydrogen and Van der Waals interactions, inhibiting transcriptional activity of AR mutants [2]. ODM-201 has been widely used in preclinical models to inhibit the progression of prostate cancer[3].
In vitro, ODM-201 treatment for 6 days significantly inhibited the viability of LNCaP/AR cells, with an IC50 value of 1.65µM[4]. Treatment with 10µM ODM-201 for 72 hours significantly inhibited the growth of C4-2 cells and induced cellular senescence, down-regulating the mRNA level of CDKN2A and the protein level of p16[5]. Treatment with 30µM ODM-201 for 4 days significantly reduced the expression of cyclin D1 in BT-549 cells, upregulated the phosphorylation of ERK, and inhibited cell proliferation[6].
In vivo, ODM-201 treatment via intraperitoneally injection at a dose of 20mg/kg/day for 14 days inhibited the tumor growth in mice with LNCaP cell xenografts[7]. Oral administration of 100mg/kg dose of ODM-201 daily for 2 months significantly inhibited tumor growth in the xenograft mouse model of KuCaP-1 prostate cancer carrying the AR W742C mutation, with limited weight loss[8].
References:
[1] Moilanen A M, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies[J]. Scientific reports, 2015, 5(1): 12007.
[2] Borgmann H, Lallous N, Ozistanbullu D, et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)[J]. European urology, 2018, 73(1): 4-8.
[3] Bastos D A, Antonarakis E S. Darolutamide for castration-resistant prostate cancer[J]. OncoTargets and therapy, 2019: 8769-8777.
[4] Yu J, Zhou P, Hu M, et al. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants[J]. European journal of medicinal chemistry, 2019, 182: 111608.
[5] Gupta S, Pungsrinont T, Ženata O, et al. Interleukin-23 represses the level of cell senescence induced by the androgen receptor antagonists enzalutamide and darolutamide in castration-resistant prostate cancer cells[J]. Hormones and Cancer, 2020, 11(3): 182-190.
[6] Kuroiwa Y, Ito K, Nakayama J, et al. Analysis of the responsiveness to antiandrogens in multiple breast cancer cell lines[J]. Genes to Cells, 2024, 29(4): 301-315.
[7] Li B, Cheng B, Huang H, et al. Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer[J]. International journal of biological sciences, 2024, 20(12): 4635.
[8] Sugawara T, Baumgart S J, Nevedomskaya E, et al. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models[J]. International journal of cancer, 2019, 145(5): 1382-1394.
ODM-201是一种强效的雄激素受体拮抗剂，Ki值为11nM，IC50值为26nM[1]。ODM-201通过氢键和范德华相互作用维持其在F877L突变口袋中的结合构象，从而抑制突变AR的转录活性[2]。ODM-201已被广泛用于临床前模型中抑制前列腺癌的进展[3]。
在体外，ODM-201处理6天显著抑制了LNCaP/AR细胞的活力，IC50值为1.65µM[4]。使用10µM的ODM-201处理C4-2细胞72小时，显著抑制了细胞生长并诱导了细胞衰老，下调了CDKN2A的mRNA水平和p16的蛋白水平[5]。使用30µM的ODM-201处理BT-549细胞4天，显著降低了细胞周期蛋白D1的表达，上调了ERK的磷酸化，并抑制了细胞增殖[6]。
在体内，每日腹腔注射20mg/kg剂量的ODM-201，连续14天，抑制了携带LNCaP细胞异种移植瘤小鼠的肿瘤生长[7]。每日口服100mg/kg剂量的ODM-201，连续2个月，显著抑制了携带AR W742C突变的KuCaP-1前列腺癌异种移植小鼠模型中的肿瘤生长，且体重减轻有限[8]。
| Cell experiment [1]: | |
Cell lines | LNCaP/AR cells |
Preparation Method | LNCaP/AR cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37℃ in the presence of 5% CO2. 2×104 cells per well were seeded in a 96-well plate for 24h, and were treated with different concentrations of ODM-201 (0.1, 1, 2, 4, 6, 8, and 10µM). After a 6-day incubation with ODM-201, cell viability was measured. |
Reaction Conditions | 0.1, 1, 2, 4, 6, 8, and 10µM; 6 days |
Applications | ODM-201 treatment significantly reduced the cell viability of LNCaP/AR cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male BALB/c nude mice |
Preparation Method | Male BALB/c nude mice (4-week-old) were housed in temperature (23±2°C) and light-controlled (12:12-hour light-dark cycle) animal care facility. Subcutaneously inject 2×106 LNCaP cells into mice. When the average tumor volume reached approximately 100mm3, the mice were intraperitoneally injected with ODM-201 (20mg/kg/day), RSL-3 (10mg/kg/day), or vehicle. The procedure was continued for 14 days. Mice were monitored daily, and the tumor volume was calculated using the following equation: volume=length×width2×1/2. |
Dosage form | 20mg/kg/day for 14 days; i.p. |
Applications | ODM-201 treatment inhibited the tumor growth in mice with LNCaP cell xenografts. |
References: | |
| Cas No. | 1297538-32-9 | SDF | |
| 别名 | 达洛鲁胺,ODM-201; BAY-1841788 | ||
| 化学名 | N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide | ||
| Canonical SMILES | N#CC1=C(Cl)C=C(C2=NN(C[C@H](C)NC(C3=NNC(C(O)C)=C3)=O)C=C2)C=C1 | ||
| 分子式 | C19H19ClN6O2 | 分子量 | 398.85 |
| 溶解度 | ≥ 19.95mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5072 mL | 12.536 mL | 25.0721 mL |
| 5 mM | 501.4 μL | 2.5072 mL | 5.0144 mL |
| 10 mM | 250.7 μL | 1.2536 mL | 2.5072 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet